西班牙Certest滅活的宋內氏志賀菌抗原（天然提取物）

廣州健侖生物科技有限公司

廣州健侖長期供應各種生物原料，主要代理品牌：西班牙Certest。

主要產品包括各種生物單克隆抗原抗體、重組蛋白。

西班牙Certest滅活的宋內氏志賀菌抗原（天然提取物）

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

【產品介紹】

西班牙Certest滅活的宋內氏志賀菌抗原（天然提取物）

這項研究的調查結果支持細胞因子治療或許可用于治療腫瘤細胞缺乏MHC I類的患者。
據西班牙《阿貝賽報》10月16日報道，新的研究成果以2013年12月介紹的初步結果為基礎，包括在費城兒童醫院治療的*25名兒童和青年患者(5歲-22歲)以及賓夕法尼亞大學醫院收治的*5名成人患者(26歲-60歲)的治療檔案?？偠灾?，參與研究試驗的30名患者在輸入自己的免疫細胞后，有27名患者的病癥得到*消除，接近于*。
費城兒童醫院醫生斯蒂芬·格魯普解釋說，參加試驗的ALL患者有些曾經4次復發，包括那些進行干細胞移植后癌癥再次復發的人，這些人占到試驗人數的60%，“他們的癌細胞侵略性很強，沒有有效治療方案，因此CTL019療法的持久效果是*的”。
CTL019實驗性療法利用的是病人自身的T細胞，這些細胞通過類似于獻血的方式采集，然后利用基因轉移技術將T細胞重新編程，“教”它們攻擊和摧毀腫瘤細胞。經過修改的細胞含有被稱為嵌合抗原受體(CAR)的抗體樣蛋白，設計該蛋白是為了讓它與B細胞表面的CD19蛋白結合，包括不同癌癥中典型的腫瘤B細胞。
一旦獲得被研究人員稱之為“抗原抗體者”(因為其具有攻擊和摧毀癌細胞的能力)的細胞，t細胞被輸回到病人體內進行繁殖并攻擊癌細胞。此外因為CAR抗原可以接受控制，研究人員讓細胞快速繁殖，宛如可以大規模殺死癌細胞的“抗原抗體者細胞*”。事實上試驗顯示，一個植入細胞可以在病人身上繁殖出1萬個新細胞。
報道稱，到目前為止，參與試驗的19名患者癥狀得到緩解，其中15名患者僅使用了這一種療法，包括一名9歲兒童，他是兩年前*個接受CTL019療法的病人。所有接受CTL019細胞的患者在接受細胞輸入幾天后都出現了細胞因子釋放綜合征，這是經過修改的細胞在患者體內繁殖和攻擊腫瘤細胞的標記，病人癥狀輕重各有不同，表現為流感、高熱、抗原抗體、肌肉疼痛、低血壓和呼吸困難等，但經過配合治療zui后這些癥狀在所抗原抗體人身上都會消失。
與此同時，那些ALL病癥*消除的患者，他們體內同樣帶有CD19蛋白的非腫瘤正常B細胞也隨著腫瘤被一起清除了。研究人員指出，接受CTL019療法后正常B細胞持續缺失說明基因改良T細胞在持續活動，相信它們可以起到類似于預防腫瘤復發的長期疫苗的作用。

西班牙

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

The findings of this study support cytokine therapy and may be used to treat patients with tumor cells lacking MHC class I.
The new study, based on preliminary results presented in December 2013, includes the first 25 children and young patients treated at Philadelphia Children's Hospital (5-year-old - 22 years old) and the first five adult patients (26-60) admitted to the University Hospital of Pennsylvania. All in all, of the 30 patients participating in the study, after entering their own immune cells, 27 of the patients had their symptoms compley eliminated and nearly recovered.
Philadelphia Children's Hospital physician Stephen Grup explains that some of the ALL patients who participated in the trial had had four recurrences, including those who relapsed after a stem cell transplant, and these accounted for 60% of the trial population. "Their cancer cells Aggressive, there is no effective treatment, so the lasting effect of CTL019 therapy is unprecedented. "
CTL019 experimental therapy uses the patient's own T cells, which are collected in a manner similar to blood donation and then reprogram T cells with gene transfer technology to "teach" them to attack and destroy tumor cells. The modified cells contain an antibody-like protein called chimeric antigen receptor (CAR) designed to bind to the CD19 protein on the surface of B cells, including typical tumor B cells in different cancers.
Once cells are known by researchers as "antigen-antibodies" (because of their ability to attack and destroy cancer cells), the t-cells are returned to the patient's body to multiply and attack the cancer cells. In addition, because CAR antigens are under control, researchers are able to multiply cells quickly, just like the "army of antigen-antibody cells" that kill cancer cells on a large scale. In fact, experiments show that one implanted cell produces 10,000 new cells in the patient.
To date, the 19 patients who participated in the trial were relieved of symptoms, 15 of whom used this therapy alone, including a 9-year-old child who was the first patient to receive CTL019 therapy two years earlier. All patients who received CTL019 cells developed cytokine release syndrome a few days after receiving the cell input, a marker of a modified cell that multiplied and attacked the tumor cells in the patient. The patient's symptoms varied in severity, manifested as flu, Fever, antigen and antibody, muscle pain, hypotension and dyspnea, but after the treatment of these symptoms in the final anti-human antibodies will disappear.
In the meantime, patients with complete elimination of ALL disease also have non-tumor-normal B cells that also carry CD19 protein in their body cleared with the tumor. The researchers pointed out that the continued absence of normal B cells following CTL019 therapy suggests that the genetically modified T cells are continuously active, believing they can act as long-term vaccines that prevent tumor recurrence.